Ze-yang Ding, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (NCT06194695) | Ze-yang Ding, MD | 2022-02-01 |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (NCT05713994) | Ze-yang Ding, MD | 2020-05-19 |
Track Ze-yang Ding, MD automatically
Every clearance here is in the API, with alerts when new ones post.